Company intelligence / Profile preview

Myrobalan Therapeutics

Medford, Massachusetts, United Statesmyrotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has nominated a preclinical candidate for the CSF1R program and is advancing MRO-002 (GPR17 antagonist) through preclinical development for multiple sclerosis

Therapeutic areas: Neurology
Modalities: Oral small molecules
Industry: Biotech

Drug pipeline

2 assets

MRO-002

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Myrobalan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myrobalan Therapeutics.

Explore the full profile